Hematology · Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Biomarkers and Genetic Testing

At a Glance

For CLL/SLL, FISH, TP53, and IGHV testing helps show how the disease may behave and which treatment is most appropriate when treatment is needed. del(17p) or TP53 mutations usually favor targeted therapy over traditional chemotherapy, while FISH and TP53 should be repeated before each new treatment line.

Before you start any treatment for CLL or SLL, biomarker testing is highly recommended by major clinical guidelines. Your specialist should look at the specific genetic makeup of your cancer cells to determine which treatments are most likely to work for your specific disease biology ^[1]^[2].

In CLL/SLL, “high-risk” genetics do not automatically mean you need treatment immediately. However, if your doctor determines that treatment is necessary because of active symptoms or falling blood counts, these genetic results guide the choice of medicine ^[3]^[4].

The Essential Tests

There are three main tests that are heavily relied upon to guide your first line of treatment:

1. FISH Testing (Fluorescence In Situ Hybridization)

This test looks for missing or extra pieces of chromosomes in your CLL cells. The FISH panel typically checks for four specific abnormalities that help predict how the disease may behave ^[5]:

del(17p): A piece of chromosome 17 is missing. This is a critical finding because it removes the TP53 gene, which is a “guardian” gene that standard chemotherapy relies on to kill cancer cells ^[6]^[7].
del(11q): A piece of chromosome 11 is missing. This is often associated with larger lymph nodes. Historically it was considered “unfavorable,” though modern targeted drugs have greatly improved outcomes for this group ^[8].
Trisomy 12: There is an extra copy of chromosome 12, considered an “intermediate” risk finding ^[5].
del(13q): A piece of chromosome 13 is missing. If this is the only abnormality found, it is generally considered a “favorable” finding, often linked to slower-growing disease ^[5]^[9].

2. TP53 Mutation Sequencing

Even if your FISH test is “normal” for chromosome 17, the TP53 gene itself can have a tiny mutation (like a typo in a book) that makes it stop working ^[1]. It is important to have both FISH and next-generation sequencing (NGS) for TP53. If the TP53 pathway is disrupted—whether through a deletion (17p) or a mutation—standard chemotherapy (like FCR or BR) is generally avoided because the disease responds poorly to it ^[6]^[10].

3. IGHV Mutation Status

This test sounds confusing because, in this case, a “mutation” is actually a good thing.

IGHV Mutated: Your B-cells are more mature. This version of the disease is typically slower-growing, and patients often have very long-lasting responses to treatment ^[11]^[12].
IGHV Unmutated: The cells are less mature. This version of the disease often requires treatment sooner and has a higher risk of resistance to traditional chemotherapy ^[11].

Why This Matters: Targeted Therapy vs. Chemotherapy

The reason these tests are so vital is that modern targeted therapies—such as BTK inhibitors (e.g., acalabrutinib, zanubrutinib) and BCL-2 inhibitors (e.g., venetoclax)—use different pathways to destroy cells ^[3]^[13].

If you have a del(17p) or a TP53 mutation, chemotherapy is typically ineffective because the genetic “switch” it relies on is broken ^[7]. Targeted therapies can bypass this roadblock and provide vastly improved disease control for patients in these high-risk groups ^[14]^[15]. However, it is important to note that even with targeted therapies, high-risk disease still carries a higher biological risk of eventually developing resistance, which is why working with a CLL specialist is so important.

A Note on Timing

Genetic markers in CLL can change over time. While your IGHV status never changes and only needs to be tested once, FISH and TP53 tests should be repeated every time you are about to start a new line of treatment, as the cancer can evolve after its first exposure to medicine ^[2]^[16]. Testing can be done on blood, bone marrow, or lymph node tissue, depending on where your disease is most active.

Common questions in this guide

Which genetic tests are important before CLL/SLL treatment?

The main tests are a FISH panel, TP53 mutation sequencing, and IGHV mutation-status testing. Together, they can show how the disease may behave and help your care team choose treatment if therapy is needed.

Does a del(17p) result or TP53 mutation mean I need treatment right away?

No. These findings indicate higher-risk disease biology, but they do not by themselves mean treatment must start immediately. If treatment becomes necessary, they help guide the choice of therapy.

What is the difference between mutated and unmutated IGHV?

Mutated IGHV usually describes a more mature form of CLL/SLL that grows more slowly and may have longer treatment responses. Unmutated IGHV is associated with disease that may need treatment sooner and may respond less well to traditional chemotherapy.

Why might targeted therapy be preferred if TP53 is abnormal?

Traditional chemotherapy relies partly on the TP53 pathway to damage and eliminate cancer cells, so it often works poorly when TP53 is deleted or mutated. Targeted medicines, including BTK inhibitors and the BCL-2 inhibitor venetoclax, use different pathways.

How often should CLL/SLL genetic testing be repeated?

IGHV status generally stays the same and usually needs to be checked only once. FISH and TP53 testing should generally be repeated before each new line of treatment because the cancer's genetic features can change over time.

Can CLL/SLL biomarker testing be done using blood?

Testing may use blood, bone marrow, or lymph node tissue, depending on where the disease is most active. Your specialist can recommend the sample that is most likely to provide useful results.

Get notified when new evidence is published on chronic lymphocytic leukemia/small lymphocytic lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (16)

1
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Wierda WG, Brown J, Abramson JS, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(3)):175-204 doi:10.6004/jnccn.2024.0018.
PMID: 38626800
2
Chronic lymphocytic leukemia: criteria for first-line therapeutic choice-an opinion paper.
Carda J, Martins Â, Alves D, Gomes M
Medical oncology (Northwood, London, England) 2025; (42(11)):493 doi:10.1007/s12032-025-03046-z.
PMID: 40996474
3
[Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC)].
Medina Á, Muntañola A, Crespo M, et al.
Medicina clinica 2025; (164(6)):305-305.e17 doi:10.1016/j.medcli.2024.10.018.
PMID: 39799061
4
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Hallek M, Al-Sawaf O
American journal of hematology 2021; (96(12)):1679-1705 doi:10.1002/ajh.26367.
PMID: 34625994
5
The Heterogeneity of 13q Deletions in Chronic Lymphocytic Leukemia: Diagnostic Challenges and Clinical Implications.
Xia C, Liu G, Liu J, et al.
Genes 2025; (16(3)) doi:10.3390/genes16030252.
PMID: 40149404
6
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
American journal of hematology 2019; (94(11)):1266-1287 doi:10.1002/ajh.25595.
PMID: 31364186
7
Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.
Almasri M, Amer M, Ghanej J, et al.
Life (Basel, Switzerland) 2022; (12(2)) doi:10.3390/life12020283.
PMID: 35207569
8
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E, Schneider C, Robrecht S, et al.
Blood 2020; (135(26)):2402-2412 doi:10.1182/blood.2019004492.
PMID: 32206772
9
Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada.
Huang SJ, Gillan TL, Gerrie AS, et al.
Genes, chromosomes & cancer 2016; (55(1)):16-24 doi:10.1002/gcc.22294.
PMID: 26391112
10
Risk-stratification in frontline CLL therapy: standard of care.
Tausch E, Schneider C, Stilgenbauer S
Hematology. American Society of Hematology. Education Program 2024; (2024(1)):457-466 doi:10.1182/hematology.2024000656.
PMID: 39644006
11
Association of Cytogenetics Aberrations and IGHV Mutations with Outcome in Chronic Lymphocytic Leukemia Patients in a Real-World Clinical Setting.
Muñoz-Novas C, González-Gascón-Y-Marín I, Figueroa I, et al.
Global medical genetics 2024; (11(1)):59-68 doi:10.1055/s-0044-1779668.
PMID: 38348157
12
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA, Tam CS, O'Brien SM, et al.
Blood 2016; (127(3)):303-9 doi:10.1182/blood-2015-09-667675.
PMID: 26492934
13
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Allan JN, Shanafelt T, Wiestner A, et al.
British journal of haematology 2022; (196(4)):947-953 doi:10.1111/bjh.17984.
PMID: 34865212
14
Prognostic Markers in the Era of Targeted Therapies.
Kang S, Ahn IE
Acta haematologica 2024; (147(1)):33-46 doi:10.1159/000533704.
PMID: 37703841
15
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stilgenbauer S, Eichhorst B, Schetelig J, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(19)):1973-1980 doi:10.1200/JCO.2017.76.6840.
PMID: 29715056
16
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.
Kadri S, Lee J, Fitzpatrick C, et al.
Blood advances 2017; (1(12)):715-727 doi:10.1182/bloodadvances.2016003632.
PMID: 29296715

This page explains CLL/SLL biomarker and genetic test results for education, not medical advice. Ask your hematologist or oncologist how your results affect treatment timing and choices.